In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units

International Journal of Antimicrobial Agents

Volumn 27, Issue 3, 2006, Pages 224-228

  Timurkaynak, Funda ^a   Can, Fusun ^a   Azap, Özlem Kurt ^a   Demirbilek, Müge ^a   Arslan, Hande ^a   Karaman, Sedef Özbalikçi ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Acinetobacter baumannii; Colistin; Multidrug resistant; Non traditional antimicrobials; Pseudomonas aeruginosa; Synergy

Indexed keywords

AGAR; ANTIINFECTIVE AGENT; AZITHROMYCIN; COLISTIN; DOXYCYCLINE; MEROPENEM; RIFAMPICIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; DILUTION; DOSE RESPONSE; DRUG ACTIVITY; DRUG INDUSTRY; ESCHERICHIA COLI; HOSPITAL INFECTION; IN VITRO STUDY; INTENSIVE CARE UNIT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATHOGENESIS; POWDER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STANDARDIZATION; STORAGE; TEMPERATURE; TITRIMETRY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 32644481380     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2005.10.012     Document Type: Article

References (29)

1. J.A. Karlowsky, D.C. Draghi, M.E. Jones, C. Thornsberry, I.R. Friedland, and D.F. Sahm Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001 Antimicrob Agents Chemother 47 2003 1681 1688
2. A.C. Gales, R.N. Jones, K.R. Forward, J. Linares, H.S. Sader, and J. Verhoef Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999) Clin Infect Dis 15 Suppl. 2 2001 104 113
3. G.C. Wood, S.D. Hanes, B.A. Boucher, M.A. Croce, and T.C. Fabian Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia Intensive Care Med 29 2003 2072 2076
4. A.S. Levin, A.A. Barone, and J. Penco Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii Clin Infect Dis 28 1999 1008 1011
5. F.D. Wang, M.L. Lin, W.S. Lee, and C.Y. Liu In vitro activities of beta-lactam antibiotics alone and in combination with sulbactam against Gram-negative bacteria Int J Antimicrob Agents 23 2004 590 595
6. A.S. Levin, C.E. Levy, A.E. Manrique, E.A. Medeiros, and S.F. Costa Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam Int J Antimicrob Agents 21 2003 58 62
7. P.G. Higgins, H. Wisplinghoff, D. Stefanik, and H. Seifert In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains Antimicrob Agents Chemother 48 2004 1586 1592
8. M.D. Appleman, H. Belzberg, and D.M. Citron In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak Antimicrob Agents Chemother 44 2000 1035 1040
9. E.J. Giamarellos-Bourboulis, H. Sambatakou, I. Galani, and H. Giamarellou In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa J Chemother 15 2003 235 238
10. G.M. Hogg, J.G. Barr, and C.H. Webb In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii J Antimicrob Chemother 41 1998 494 495
11. C. Tascini, F. Menichetti, S. Bozza, A. Del Favero, and F. Bistoni Evaluation of the activities of two-drug combinations of rifampicin, polymyxin B and ampicillin/sulbactam against Acinetobacter baumannii J Antimicrob Chemother 42 1998 270 271
12. J. Yoon, C. Urban, C. Terzian, N. Mariano, and J.J. Rahal In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii Antimicrob Agents Chemother 48 2004 753 757
13. E.J. Giamarellos-Bourboulis, E. Xirouchaki, and H. Giamarellou Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii Diagn Microbiol Infect Dis 40 2001 117 120
14. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 6th ed: Approved Standard M7-A6. Wayne, PA: NCCLS; 2003.
15. C.R. Catchpole, J.M. Andrews, N. Brenwald, and R.J. Wise A reassessment of the in-vitro activity of colistin sulphomethate sodium J Antimicrob Chemother 39 1997 255 260
16. Moody J. Synergism testing: broth microdilution checkerboard and broth macrodilution methods. In: Isenberg HD, editor. Clinical microbiology procedures handbook. 2nd ed. Washington, DC: ASM Press; 2004. p. 1-28.
17. N. Markou, H. Apostolakos, and C. Koumoudiou Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients Crit Care 7 2003 R78 R83
18. R.E. Hancock, and D.S. Chapple Peptide antibiotics Antimicrob Agents Chemother 43 1999 1317 1323
19. A.I. Duenas Diez, M.A. Bratos Perez, and J.M. Eiros Bouza Susceptibility of the Acinetobacter calcoaceticus-A. baumannii complex to imipenem, meropenem, sulbactam and colistin Int J Antimicrob Agents 23 2004 487 493
20. E.J. Giamarellos-Bourboulis, L. Karnesis, and H. Giamarellou Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia Diagn Microbiol Infect Dis 44 2002 259 263
21. B.W. Gunderson, K.H. Ibrahim, L.B. Hovde, T.L. Fromm, M.D. Reed, and J.C. Rotschafer Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model Antimicrob Agents Chemother 47 2003 905 909
22. C. Tascini, G. Gemignani, and S. Ferranti Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections J Chemother 16 2004 282 287
23. M.E. Falagas, I.A. Bliziotis, S.K. Kasiakou, G. Samonis, P. Athanassopoulou, and A. Michalopoulos Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria BMC Infect Dis 5 2005 24
24. A.S. Michalopoulos, S. Tsiodras, K. Rellos, S. Mentzelopoulos, and M.E. Falagas Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic Clin Microbiol Infect 11 2005 115 121
25. M.J. Rodriguez-Hernandez, J. Pachon, and C. Pichardo Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia J Antimicrob Chemother 45 2000 493 501
26. C. Thornsberry, B.C. Hill, J.M. Swenson, and L.K. McDougal Rifampin: spectrum of antibacterial activity Rev Infect Dis 5 Suppl. 3 1983 S412 S417
27. M. Wolff, M.L. Joly-Guillou, R. Farinotti, and C. Carbon In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model Antimicrob Agents Chemother 43 1999 1406 1411
28. E. Bergogne-Berezin The increasing role of Acinetobacter species as nosocomial pathogens Curr Infect Dis Rep 3 2001 440 444
29. F. Fernandez-Cuenca, L. Martinez-Martinez, A. Pascual, and E.J. Perea In vitro activity of azithromycin in combination with amikacin, ceftazidime, ciprofloxacin or imipenem against clinical isolates of Acinobacter baumannii Chemotherapy 49 2003 24 26